Several significant safety concerns warrant consideration
In an observational study, individuals that have T2DM, GLP-1RA therapy, Liraglutide, reduced pro-inflammatory cytokines (e.g., TNF-, interleukin-1 beta (IL-1), IL-6) in PBMCs, and increased serum adipokine, adiponectin, and macrophage activation markers (sCD163) [95]
Despite the development and testing of various therapeutic strategies aimed at mitigating neurological decline after TBI, a definitive cure for these conditions remains elusive
Unlike systemic IGF-1, MGF remains locally active, with preclinical studies indicating roles in satellite cell recruitment, myoblast proliferation, and differentiation timing in mechanically stimulated tissue
807 Several animal experiments have demonstrated that antioxidants and active substances from Chinese medicine reduce myocardial I/R Injury and ferroptosis in ischemic cardiomyopathy animals, and protect myocardial function
Clinical Evidence in Asian Indian Patients The Indian thin fat phenotype is more prone to the development of T2DM and is associated with several unique features, such as early age of T2DM onset, early decline in beta cell mass, higher insulin resistance, higher carbohydrate intake and physical inactivity leading to central obesity, unique dyslipidemia pattern, increased CV disease risk, higher association with nonalcoholic fatty liver disease, among others [29,30,31]
